Here we report on the mechanism underlying the sensitivity and acquired resistance of these cell lines to gefitinib, and discuss possible molecular targeting therapy against patients with HER2-overexpressing gastric cancer liver metastasis. Here, ERBB2 is linked to gastric cancer.